Cover Image
市場調查報告書

XBiotech USA, Inc.:產品平台分析

XBiotech USA, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 257885
出版日期 內容資訊 英文 33 Pages
訂單完成後即時交付
價格
Back to Top
XBiotech USA, Inc.:產品平台分析 XBiotech USA, Inc. - Product Pipeline Review - 2015
出版日期: 2015年09月16日 內容資訊: 英文 33 Pages
簡介

生物製藥公司XBiotech USA, Inc.利用該公司有力藥劑候補進行第Ⅰ/Ⅱ代臨床實驗,提供腫瘤,MRSA,循環系統疾病,皮膚相關解決方案。同時該公司更藉由製造技術提供了前所未有的低價格產品。

本報告提供XBiotech USA, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,同時也提供最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

XBiotech USA, Inc.的基本資料

XBiotech USA, Inc.概要

  • 主要資訊
  • 企業資料

XBiotech USA, Inc.:R&D概要

  • 主要的治療範圍

XBiotech USA, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

XBiotech USA, Inc.:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

XBiotech USA, Inc.:藥物簡介

  • Xilonix
  • CV-18C3
  • RA-18C3
  • T2-18C3
  • CA-18C3
  • MABp-1
  • Biosimilar for Inflammation
  • Biosimilar for Oncology
  • filgrastim
  • MonoClonal Antibody for Methicillin Resistant Staphylococcus Aureus
  • Monoclonal Antibody to Inhibit IL-1A for Rheumatoid Arthritis and Myeloma
  • Monoclonal Antibody for Influenza
  • Monoclonal Antibody for Vascular diseases
  • Monoclonal Antibody to Inhibit Interleukin-6 for Autoimmune Disorder and Transplantation

XBiotech USA, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

XBiotech USA, Inc.:最近的開發平台趨勢

XBiotech USA, Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07577CDB

Summary

Global Markets Direct's, 'XBiotech USA, Inc. - Product Pipeline Review - 2015', provides an overview of the XBiotech USA, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of XBiotech USA, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of XBiotech USA, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of XBiotech USA, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the XBiotech USA, Inc.'s pipeline products

Reasons to buy

  • Evaluate XBiotech USA, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of XBiotech USA, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the XBiotech USA, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of XBiotech USA, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of XBiotech USA, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of XBiotech USA, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • XBiotech USA, Inc. Snapshot
    • XBiotech USA, Inc. Overview
    • Key Information
    • Key Facts
  • XBiotech USA, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • XBiotech USA, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • XBiotech USA, Inc. - Pipeline Products Glance
    • XBiotech USA, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • XBiotech USA, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • XBiotech USA, Inc. - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • XBiotech USA, Inc. - Drug Profiles
    • Xilonix
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CV-18C3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RA-18C3
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Methicillin Resistant Staphylococcus Aureus
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Ebola Viral Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • XBiotech USA, Inc. - Pipeline Analysis
    • XBiotech USA, Inc. - Pipeline Products by Target
    • XBiotech USA, Inc. - Pipeline Products by Route of Administration
    • XBiotech USA, Inc. - Pipeline Products by Molecule Type
    • XBiotech USA, Inc. - Pipeline Products by Mechanism of Action
  • XBiotech USA, Inc. - Recent Pipeline Updates
  • XBiotech USA, Inc. - Dormant Projects
  • XBiotech USA, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • XBiotech USA, Inc., Key Information
  • XBiotech USA, Inc., Key Facts
  • XBiotech USA, Inc. - Pipeline by Indication, 2015
  • XBiotech USA, Inc. - Pipeline by Stage of Development, 2015
  • XBiotech USA, Inc. - Monotherapy Products in Pipeline, 2015
  • XBiotech USA, Inc. - Phase III, 2015
  • XBiotech USA, Inc. - Phase II, 2015
  • XBiotech USA, Inc. - Phase I, 2015
  • XBiotech USA, Inc. - Discovery, 2015
  • XBiotech USA, Inc. - Pipeline by Target, 2015
  • XBiotech USA, Inc. - Pipeline by Route of Administration, 2015
  • XBiotech USA, Inc. - Pipeline by Molecule Type, 2015
  • XBiotech USA, Inc. - Pipeline Products by Mechanism of Action, 2015
  • XBiotech USA, Inc. - Recent Pipeline Updates, 2015
  • XBiotech USA, Inc. - Dormant Developmental Projects,2015

List of Figures

  • XBiotech USA, Inc. - Pipeline by Top 10 Indication, 2015
  • XBiotech USA, Inc. - Pipeline by Stage of Development, 2015
  • XBiotech USA, Inc. - Monotherapy Products in Pipeline, 2015
  • XBiotech USA, Inc. - Pipeline by Top 10 Target, 2015
  • XBiotech USA, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • XBiotech USA, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • XBiotech USA, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top